Unusual Volume Noted in Tuesday's ETF: IVE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Source: NASDAQ.COM
ETF Performance: The iShares S&P 500 Value ETF saw significant trading volume on Tuesday, with Ford Motor and Warner Bros. Discovery showing notable gains.
Top Performers: Medtronic was the best-performing component of the ETF, rising by approximately 5.8%, while Western Digital experienced a decline of about 4.6%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 101.080
Low
102.00
Averages
111.76
High
120.00
Current: 101.080
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic to Report Q3 FY2026 Financial Results on February 17
- Earnings Release Date: Medtronic will report its financial results for the third quarter of fiscal year 2026 on February 17, 2026, with the report expected to reflect the company's ongoing performance in the healthcare technology sector.
- Webcast Arrangement: Following the earnings release, a video webcast will commence at 7:00 a.m. CST, allowing investors to access the discussion through the company's investor relations website, thereby enhancing transparency and fostering investor engagement.
- Financial Information Access: Within 24 hours post-webcast, investors can access a replay and transcript of the prepared remarks on the company’s website, ensuring timely availability of critical information for stakeholders.
- Company Background Overview: Headquartered in Galway, Ireland, Medtronic is dedicated to addressing global health challenges with over 95,000 employees, offering a range of medical technologies including cardiac devices and surgical robotics, underscoring its leadership position in the industry.
See More
Medtronic to Report Q3 FY2026 Financial Results on February 17
- Earnings Announcement: Medtronic has announced that it will report its financial results for the third quarter of fiscal year 2026 on February 17, 2026, covering data up to January 23, 2026, reflecting the company's ongoing performance in the healthcare technology sector.
- Global Leadership: As a leading global healthcare technology company, Medtronic is committed to addressing significant health challenges, employing over 95,000 people across more than 150 countries, showcasing its strong global influence.
- Technologies and Therapies: The company offers technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, and insulin pumps, demonstrating its broad application and market demand in medical innovation.
- Mission and Vision: Medtronic's mission is to alleviate pain, restore health, and extend life, emphasizing a people-first care experience and a commitment to improving global health outcomes through innovative technologies.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- Market Reaction Insight: While specific company names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: Investors considering buying RBLX stock should pay attention to analysts' opinions, as these insights may impact market sentiment and stock performance.
- Rating Change Transparency: Benzinga provides a comprehensive view of analyst rating changes, assisting investors in obtaining complete information to make more informed investment decisions.
See More
Major Wall Street Rating Updates on Monday
- Robinhood Upgrade: Wolfe upgraded Robinhood from Peer Perform to Outperform to capitalize on the recent selloff due to deteriorating sentiment in the crypto ecosystem, indicating that investors should seize the buying opportunity.
- Bullish on TeraWulf and Cipher Mining: Morgan Stanley initiated coverage on TeraWulf and Cipher Mining with an Overweight rating, citing significant upside potential from attractive valuations in the bitcoin mining sector.
- Timken's New CEO Drives Growth: KeyBanc upgraded Timken from Sector Weight to Overweight with a $130 price target, primarily based on expectations that new CEO Lucian Boldea will enhance organic growth initiatives and improve margins.
- Align Technologies Brand Strength: HSBC upgraded Align Technologies from Hold to Buy, emphasizing that its strong brand presence and R&D culture are key long-term growth drivers in the orthodontics market.
See More
Analysis of Strong Dividend Stocks: Johnson & Johnson and Medtronic
- Dividend Growth Performance: Johnson & Johnson (JNJ) extended its dividend growth streak to 63 years in 2025 with a 4.8% increase, boasting a 2.2% dividend yield that is nearly double the S&P 500, showcasing its exceptional performance in dividend growth and enhancing investor confidence.
- Financial Health: Last year, Johnson & Johnson generated $20 billion in free cash flow, easily covering its $12.4 billion in dividend payouts, and holds a AAA credit rating, ensuring its ability to maintain dividend payments and stability for future investments.
- R&D Investment: Johnson & Johnson invested $14.7 billion in R&D and completed a $14.6 billion acquisition of Intra-Cellular Therapies, solidifying its leadership in neuroscience, which will further drive its earnings and dividend growth.
- Medtronic's Dividend Stability: Medtronic (MDT) achieved its 48th consecutive dividend increase in fiscal year 2025 with a 2.8% yield, supported by $5.2 billion in free cash flow that comfortably covers $3.6 billion in dividends, reflecting its strong financial position and growth potential.
See More
Eli Lilly's Stock Rises Sharply Due to Increased Demand for GLP-1 Drugs
- Stock Performance: Eli Lilly's stock has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, indicating strong performance in the GLP-1 drug market, although its high P/E ratio of 49 may deter some investors.
- Competitive Landscape: While Novo Nordisk ranks second in the GLP-1 drug market, its newly launched GLP-1 pill is seeing demand exceed expectations, potentially driving future growth, despite its stock being down 66% from 2024 highs.
- Medical Device Restructuring: Medtronic plans to spin off its diabetes business in 2026; although this division has been growing rapidly, its lower margins mean that the spinoff will enhance overall profitability and accelerate growth in its higher-margin sectors.
- Future Growth Potential: Despite Eli Lilly's strong performance in the GLP-1 market, Novo Nordisk's pill catalyst could help it regain momentum, while Medtronic's restructuring may unlock significant growth potential, making both companies worthy of investor attention.
See More
Medtronic to Report Q3 FY2026 Financial Results on February 17
- Earnings Release Date: Medtronic will report its financial results for the third quarter of fiscal year 2026 on February 17, 2026, with the report expected to reflect the company's ongoing performance in the healthcare technology sector.
- Webcast Arrangement: Following the earnings release, a video webcast will commence at 7:00 a.m. CST, allowing investors to access the discussion through the company's investor relations website, thereby enhancing transparency and fostering investor engagement.
- Financial Information Access: Within 24 hours post-webcast, investors can access a replay and transcript of the prepared remarks on the company’s website, ensuring timely availability of critical information for stakeholders.
- Company Background Overview: Headquartered in Galway, Ireland, Medtronic is dedicated to addressing global health challenges with over 95,000 employees, offering a range of medical technologies including cardiac devices and surgical robotics, underscoring its leadership position in the industry.
See More
Medtronic to Report Q3 FY2026 Financial Results on February 17
- Earnings Announcement: Medtronic has announced that it will report its financial results for the third quarter of fiscal year 2026 on February 17, 2026, covering data up to January 23, 2026, reflecting the company's ongoing performance in the healthcare technology sector.
- Global Leadership: As a leading global healthcare technology company, Medtronic is committed to addressing significant health challenges, employing over 95,000 people across more than 150 countries, showcasing its strong global influence.
- Technologies and Therapies: The company offers technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, and insulin pumps, demonstrating its broad application and market demand in medical innovation.
- Mission and Vision: Medtronic's mission is to alleviate pain, restore health, and extend life, emphasizing a people-first care experience and a commitment to improving global health outcomes through innovative technologies.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- Market Reaction Insight: While specific company names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: Investors considering buying RBLX stock should pay attention to analysts' opinions, as these insights may impact market sentiment and stock performance.
- Rating Change Transparency: Benzinga provides a comprehensive view of analyst rating changes, assisting investors in obtaining complete information to make more informed investment decisions.
See More
Major Wall Street Rating Updates on Monday
- Robinhood Upgrade: Wolfe upgraded Robinhood from Peer Perform to Outperform to capitalize on the recent selloff due to deteriorating sentiment in the crypto ecosystem, indicating that investors should seize the buying opportunity.
- Bullish on TeraWulf and Cipher Mining: Morgan Stanley initiated coverage on TeraWulf and Cipher Mining with an Overweight rating, citing significant upside potential from attractive valuations in the bitcoin mining sector.
- Timken's New CEO Drives Growth: KeyBanc upgraded Timken from Sector Weight to Overweight with a $130 price target, primarily based on expectations that new CEO Lucian Boldea will enhance organic growth initiatives and improve margins.
- Align Technologies Brand Strength: HSBC upgraded Align Technologies from Hold to Buy, emphasizing that its strong brand presence and R&D culture are key long-term growth drivers in the orthodontics market.
See More
Analysis of Strong Dividend Stocks: Johnson & Johnson and Medtronic
- Dividend Growth Performance: Johnson & Johnson (JNJ) extended its dividend growth streak to 63 years in 2025 with a 4.8% increase, boasting a 2.2% dividend yield that is nearly double the S&P 500, showcasing its exceptional performance in dividend growth and enhancing investor confidence.
- Financial Health: Last year, Johnson & Johnson generated $20 billion in free cash flow, easily covering its $12.4 billion in dividend payouts, and holds a AAA credit rating, ensuring its ability to maintain dividend payments and stability for future investments.
- R&D Investment: Johnson & Johnson invested $14.7 billion in R&D and completed a $14.6 billion acquisition of Intra-Cellular Therapies, solidifying its leadership in neuroscience, which will further drive its earnings and dividend growth.
- Medtronic's Dividend Stability: Medtronic (MDT) achieved its 48th consecutive dividend increase in fiscal year 2025 with a 2.8% yield, supported by $5.2 billion in free cash flow that comfortably covers $3.6 billion in dividends, reflecting its strong financial position and growth potential.
See More
Eli Lilly's Stock Rises Sharply Due to Increased Demand for GLP-1 Drugs
- Stock Performance: Eli Lilly's stock has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, indicating strong performance in the GLP-1 drug market, although its high P/E ratio of 49 may deter some investors.
- Competitive Landscape: While Novo Nordisk ranks second in the GLP-1 drug market, its newly launched GLP-1 pill is seeing demand exceed expectations, potentially driving future growth, despite its stock being down 66% from 2024 highs.
- Medical Device Restructuring: Medtronic plans to spin off its diabetes business in 2026; although this division has been growing rapidly, its lower margins mean that the spinoff will enhance overall profitability and accelerate growth in its higher-margin sectors.
- Future Growth Potential: Despite Eli Lilly's strong performance in the GLP-1 market, Novo Nordisk's pill catalyst could help it regain momentum, while Medtronic's restructuring may unlock significant growth potential, making both companies worthy of investor attention.
See More
